Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...

Content from other channels on our network

Stigma around lung disease and cancer must go

Queensland announces its Hospital Rescue Plan

Report card shows "alarming" levels of ramping

NSW commits additional $2.8m for paediatric palliative care

High-five for a sustainable path to better hand hygiene

JCU develops 'world first' bendable ceramic

Bayan licenses Australian solar cell recycling technology

Visy smashes recycled glass content target in New Zealand

Nuclear places Australia's aluminium smelters at risk: analysis

Construction begins on Central Coast Food Manufacturing Innovation Hub

Safeguarding food and beverage production processes

Australia's Industrial Future Takes Centre Stage in Sydney This July

Premium snack maker meets growing demand

Sauerkraut better than raw cabbage for gut health

Heat exchangers expand ginger beer production

  • All content Copyright © 2025 Westwick-Farrow Pty Ltd